SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Extends Review for Astellas Pharma Inc. (Jobs) Fungal Drug New Use

September 4, 2007 | 
1 min read
TOKYO, Sept 3 (Reuters) - U.S. health authorities have extended by three months their review of Astellas Pharma Inc's application for fungal drug Mycamine to be used for additional indications, the company said on Monday.
Regulatory Asia
Astellas Pharma US, Inc. Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Illustration showing a downward graph trend
Regulatory
Future of Aardvark’s Prader-Willi drug in doubt as FDA slaps full hold on program
May 15, 2026
 · 
2 min read
 · 
Tristan Manalac
Businessperson group is walking towards career success or a vacant promotion competition. isometric vector illustration.
FDA
Biotech leaders pitch Pazdur as next FDA chief
May 14, 2026
 · 
2 min read
 · 
Annalee Armstrong
Editable vector illustration of a man winning a race. Hi-res jpeg file included.
Approvals
BeOne wins mantle cell lymphoma approval, opening new therapy class
May 14, 2026
 · 
2 min read
 · 
Tristan Manalac
Businessman pulling rope trying to lift up falling graph.
Complete response letters
UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged
May 13, 2026
 · 
3 min read
 · 
Annalee Armstrong